Kornimate/medical-research-clean huggingface dataset:
autologous platelet-rich plasma intra-ovarian infusion in poor responders

Conditions: Ovary; Anomaly; Infertility, Female

Summary: autologous prp intra ovarian infusion may improve ovarian response, patients' hormonal profile as well as fresh embryo transfer (et)-icsi cycles' outcome in patients presenting with poor ovarian response (por).

this triple-blind randomized controlled trial (rct) aims to investigate the effectiveness of autologous prp intra ovarian infusion on improving ovarian tissue functionality and fresh et-icsi cycles' performance in regard to patients presenting with por. prp is blood plasma prepared from fresh whole blood that has been enriched with platelets. it is collected from peripheral veins and contains several growth factors such as vascular endothelial growth factor (vegf), epidermal growth factor (egf), platelet derived growth factor (pdgf), transforming growth factor (tgf) and other cytokines all of which stimulate tissue proliferation and growth. prp has been employed in several medical conditions in orthopedics, dermatology, and ophthalmology for wound healing. it's efficacy in ovarian rejuvenation and reactivation and endometrial regeneration has not been fully elucidated. this study aims to investigate the effect of autologous prp intra ovarian infusion on improving ovarian tissue functionality in por patients.

Eligibility criteria:
inclusion criteria: * poor ovarian response according to bologna criteria (fulfilling 2 out of 3 of the following) * age ≥ 40 years * amh \< 1.1 ng/ml or afc \< 7 * ≤ 3 oocytes with a conventional stimulation protocol) * discontinuation of any complementary/adjuvant treatment including hormone replacement, acupuncture, and botanotherapy, for at least three months prior to recruitment. * willing to comply with study requirements exclusion criteria: * any pathological disorder related to reproductive system anatomy * cycle irregularities * amenorrhea * endometriosis * adenomyosis * fibroids and adhesions * infections in reproductive system * current or previous diagnosis of cancer in reproductive system * history of familiar cancer in reproductive system * severe male factor infertility * prior referral for pgt * ovarian inaccessibility -endocrinological disorders (hypothalamus- * pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome) * bmi\>30 kg/m2 or bmi\<18.5 kg/m2 * systematic autoimmune disorders
longitudinal measurements of flow in cerebrospinal fluid shunts with a wireless thermal anisotropy measurement device

Conditions: Hydrocephalus

Summary: this study evaluates the performance of a device for non-invasively assessing cerebrospinal fluid (csf) shunt flow. patients with an existing implanted shunt will wear the device to acquire longitudinal data.


Eligibility criteria:
inclusion criteria: 1. at least one existing ventricular csf shunt (functional or non-functional, including "virtual off" and ligated, orphaned, abandoned, tied-off, or fractured distal catheters) 2. region(s) of intact skin overlying at least one unambiguously identifiable chronically indwelling ventricular shunt which crosses the clavicle and is appropriate in size for application of the study device 3. available for remote and in-person follow-up during the 30-day measurement period (for subjects using the study device at home) 4. subject is expected to remain in an inpatient setting for sufficient time to complete all required study device measurements (for subjects using the device in an inpatient hospital setting) 5. signed informed consent by subject or a parent, legal guardian, health care agent, or surrogate decision maker (according to local statutes) 6. subject or caregiver is able to clearly communicate and document information and shunt symptoms in english 7. verbal assent by minors 12 years of age and older who are able to understand the study and communicate their decision 8. patient is at least 5 years old but not more than 80 years old exclusion criteria: 1. presence of an interfering open wound or edema over any portion of the shunt 2. patient-reported history of adverse skin reactions to adhesives 3. investigator judges that the subject is likely to be lost to follow-up due to unavailability or clinical outcome being unobtainable 4. investigator judges that the subject is unlikely to successfully take reliable measurements at home (for subjects using the study device at home) 5. investigator judges that the subject/subject's caretaker would not be able to successfully place the device without assistance 6. use of the study device would interfere with standard patient care, or emergency surgery that cannot be delayed, or participation in the study will interfere with, or be detrimental to, administration of optimal healthcare to the subject 7. participation in any other investigational procedural, pharmaceutical, and/or device study that may influence the collection of valid data under this study
how microbes and metabolism may predict skin cancer immunotherapy outcomes

Conditions: Autoimmunity; Melanoma; Merkel Cell Carcinoma; Squamous Cell Carcinoma of the Skin; Basal Cell Carcinoma; Skin Cancer

Summary: the purpose of this research study is to examine the relationship between the microbiota (microscopic organisms) in the gut and the activity of the immune system during skin cancer immunotherapy.

details will be available upon publication.

Eligibility criteria:
inclusion criteria: * ≥18 years of age. * diagnosis of skin cancer. * planning to initiate or already on any type of immunotherapy. * able to provide urine and stool specimens. exclusion criteria: * bowel resection. * major gi surgery in the past 5 years other than cholecystectomy and appendectomy.
the effect of intravenous dexamethasone on rebound pain after interscalene brachial plexus block for shoulder surgery

Conditions: Rebound Pain

Summary: the rebound pain after nerve block could interfere with the patient's recovery and rehabilitation. it is not known how intravenous dexamethasone affects rebound pain. this study aims to evaluate the effect of intravenous dexamethasone on rebound pain after interscalene block for shoulder surgery.

shoulder rotator cuff repair and acromioplasty are associated with severe postoperative pain. the interscalene block (isb) is commonly used for this type of surgery, providing analgesia by anesthetizing the nerves that supply the shoulder. although the nerve block provides extremely effective analgesia for the first 6-8 hours, patients experience severe pain once its effect has been wearing off. rebound pain is a severe pain that occurs when the effect of a nerve block disappears in a patient during the postoperative period. the purpose of this study is to investigate whether the use of intravenous dexamethasone reduces rebound pain in patients recruiting for shoulder surgery with interscalene brachial plexus blockade. this study will be conducted as a single-center, prospective, randomized, double-blinded trial in a university hospital. patients scheduled for elective shoulder surgery will be screened for enrollment in the study. all subjects will undergo ultrasound-guided interscalene nerve block before induction of general anesthesia. they will be randomly assigned into the two groups which use intravenous dexamethasone or not. an anesthesiologist who will perform blocks will not involve in the data collection. other health care workers who will involve in the evaluation of postoperative pain scores, nausea and vomiting, opioid consumption, quality of sleep, and quality of recovery score will be blinded to the group assignment.

Eligibility criteria:
inclusion criteria: * undergoing shoulder surgery * having signed a written informed consent form, * asai-iii exclusion criteria: * inadequate indication for interscalene block (coagulation disorder, local infection of block site, diaphragmatic paralysis, allergy to local anesthetics) * neuropathic disorder * severe cardiopulmonary disease * systemic steroid use * chronic opioids use * stomach ulcer * ucontrolled diabetes * psychiatric disorders, * pregnancy, * severe obesity (body mass index \> 35 kg/m2)

Keywords: interscalene brachial plexus block shoulder surgery dexamethasone
risk factors for glaucoma in musicians

Conditions: Glaucoma

Summary: the purpose of this study is to determine the impact of playing wind instruments for the development of ocular hypertension and glaucoma, together with investigating the prevalence of visual problems and eye diseases in (professional) musicians.


Eligibility criteria:
inclusion criteria: * all full time or part time professional players of participating symphony or wind orchestras, including guest players. * retired players, if possible. exclusion criteria: * difficulty in reading or speaking dutch.

Keywords: glaucoma wind instruments
ethyl-epa treatment of prodromal patients

Conditions: Schizophrenia Prodrome

Summary: this is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.


Eligibility criteria:
inclusion criteria: * meets criteria for schizophrenia prodrome exclusion criteria: * any lifetime antipsychotic treatment
community-designed food is medicine for adults with diabetes

Conditions: Diabetes Mellitus

Summary: the goal of this clinical trial is to learn if an educational intervention can affect clinical outcomes in adults with diabetes. the main question it aims to answer is: can a food is medicine intervention affect obesity and/or diabetes markers in adults? researchers will compare a food is medicine arm to a control arm to answer the research question. participants will provide biometrics and questionnaire responses at three time points. those in the food is medicine arm will receive regular free meal kits combined with cooking and nutritional education.


Eligibility criteria:
inclusion criteria: * age 18+ years, weight 100+ pounds, hba1c \>7% in 2020 exclusion criteria: -
adherence to secondary prevention guidelines for cardiovascular risk

Conditions: Atherosclerosis; Stroke, Ischemic; Acute Coronary Syndrome; Ischemic Heart Disease; Peripheral Arterial Disease

Summary: the present observational study aims to determine the degree of adherence to the recommendations of clinical guidelines regarding the prevention of cardiovascular complications in patients hospitalized due to a cardiovascular event.


Eligibility criteria:
inclusion criteria: * admitted to the cardiology, neurology, or general surgery departments * with any of the following admission diagnoses: non-st-segment elevation acute coronary syndrome (nsteacs) st-segment elevation acute coronary syndrome (steacs) stable angina unstable angina non-st-segment elevation myocardial infarction (nstemi) st-segment elevation myocardial infarction (stemi) atherothrombotic ischemic stroke lacunar stroke peripheral artery disease chronic ischemia of lower limbs vascular ulcer due to arterial cause exclusion criteria: * patients for whom lipid-lowering treatment is ruled out due to limited life expectancy * patients likely to die during hospitalization * patients who died during hospitalization
the protective effect of friendship on peer rejection in overweight and normal weight youth

Conditions: Social Exclusion; Control

Summary: this study examines youth's motivation for food or social rewards after a brief episode of simulated ostracism. the investigators hypothesize that youth who think about a friend after being ostracized will mediate their decision to resort to food, which is typically evidenced in socially isolated overweight youth.


Eligibility criteria:
inclusion criteria: * general liking for all study foods exclusion criteria: * food allergies * medical or psychological disorders
a multicenter prospective cohort study of adjuvant therapy for brca1/2 mutated hormone receptor-positive her2-negative early high-risk breast cancer

Conditions: Breast

Summary: to evaluate the efficacy and safety of different adjuvant treatment options after surgery for early high-risk breast cancer with brca1/2 mutation hr+/her2


Eligibility criteria:
inclusion criteria: * ecog score 0-1 * er\>10%, pr\>10%, her2(0)/her2(1+)/her2(2+) and no amplification of fish * brca1/2 gene mutation * no other site metastases were detected by imaging evaluation after surgical treatment * non-pcr breast cancer after neoadjuvant therapy, or breast cancer with postoperative pathology indicating ≥pn2 * the patient had no major organ dysfunction exclusion criteria: * allergic to the investigational drug, inability to take the drug orally, or refusal of the medication regimen * has been enrolled in another study or has been discontinued for less than or equal to 4 weeks * there is serious dysfunction of vital organs (heart, liver, kidney) * patients with other malignancies, except cured non-melanoma skin cancer, cervical carcinoma in situ and other tumors that have been cured for at least 5 years * in other acute infectious disease or chronic infectious disease activity period * a history of uncontrolled seizures, central nervous system disorders, or mental disorders * there is a known history of human immunodeficiency virus

Keywords: brca1/2 mutation
a study to evaluate the efficacy and safety of ad-208

Conditions: Androgenetic Alopecia

Summary: the purpose of this study is to evaluate the efficacy and safety of ad-208.

the purpose of this study is to evaluate the efficacy and safety of ad-208 in male patients with androgenetic alopecia.

Eligibility criteria:
inclusion criteria: * male patients aged 18-50 years, inclusive * patients who meet the appropriate criteria according to the classification of hair loss * signed informed consent exclusion criteria: * patients with hair loss disorders other than androgenetic alopecia * other exclusions applied
a safety and efficacy study of botox® in korean adults with chronic migraine

Conditions: Migraine Disorders

Summary: this study will evaluate the safety and efficacy of botox® treatment in korean adults with chronic migraine.


Eligibility criteria:
inclusion criteria: * ethnically korean with a diagnosis of chronic migraine exclusion criteria: * anticipated need for botulinum toxin treatment for any reason other than chronic migraine during the study * diagnosis of myasthenia gravis, eaton-lambert syndrome, or amyotrophic lateral sclerosis
fenretinide in treating patients with leukoplakia of the mouth

Conditions: Head and Neck Cancer

Summary: rationale: chemoprevention therapy is the use of certain drugs to try to prevent the development of or treat early cancer. fenretinide may be an effective drug in treating leukoplakia. purpose: randomized phase ii trial to study the effectiveness of fenretinide in treating patients who have leukoplakia of the mouth.

objectives: i. determine modulation by fenretinide of surrogate endpoint markers of oral mucosal carcinogenesis in patients with oral dysplastic leukoplakia. ii. determine whether fenretinide will cause significant modulation of intermediate endpoint markers and significant regression of oral dysplastic leukoplakia in this patient population. iii. compare the ability of fenretinide and placebo to modulate surrogate endpoint biomarkers in this patient population. iv. document the degree of recurrence of oral dysplastic leukoplakia after the administration of fenretinide, both at the same site and at new sites. outline: this is a randomized, double blind, placebo controlled study. patients are randomized to 1 of 2 treatment arms: arm i: patients receive oral fenretinide daily (except days 1-3 each month) for 6 months. arm ii: patients receive oral placebo daily (except days 1-3 each month) for 6 months. patients then receive oral fenretinide daily (except days 1-3 each month) for 6 months. patients are followed every 3 months. projected accrual: a total of 30 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically proven dysplastic leukoplakia greater than 1 cm in diameter patient characteristics: age: 18 and over performance status: ecog 0-2 life expectancy: not specified hematopoietic: wbc at least 3,500/mm3 platelet count at least 125,000/mm3 hemoglobin at least 12.0 g/dl hepatic: bilirubin less than 1.5 mg/dl sgot less than 2 times upper limit of normal (uln) renal: creatinine less than 1.7 mg/dl cardiovascular: no symptomatic coronary artery disease no uncontrolled hypertension no prior coronary artery bypass no acute myocardial infarction in the past year other: not pregnant or nursing negative pregnancy test fertile patients must use effective barrier contraception for 1 month prior, during, and for 12 months after study fasting serum triglyceride less than 2 times uln cholesterol less than 350 mg/dl no hypersensitivity to vitamin a or retinoids no active malignancy no concurrent acute or chronic medical or psychiatric condition that would preclude compliance or toxicity assessment no concurrent and severe night blindness prior concurrent therapy: biologic therapy: not specified chemotherapy: not specified endocrine therapy: not specified radiotherapy: not specified surgery: not specified other: at least 3 months since prior chronic high dose (greater than 30,000 iu/day) vitamin a (retinol) at least 1 month since other prior retinoids

Keywords: lip and oral cavity cancer
cerebellar repetitive transcranial magnetic stimulation (rtms) for the treatment of alcohol use disorder

Conditions: Alcohol Use Disorder

Summary: the objective of the current study is to investigate the effects of repetitive transcranial magnetic stimulation (rtms) on self-reported negative affect, cerebellar brain activation and alcohol use outcomes in alcohol use disorder (aud).

to achieve study aims, 34 treatment seeking adults with aud will be recruited from local intensive outpatient (iop) treatment programs and randomized to treatment with either inhibitory 1hz rtms to cerebellar vermis given daily for 2 weeks (total of 10 sessions) or sham. alcohol use outcomes, self-reported negative affect, and craving will be obtained at baseline, 1 day, 1 week and 6 weeks following rtms termination. an fmri scan during a stroop task will be obtained at baseline and 1 day after the final rtms session.

Eligibility criteria:
inclusion criteria: * males and females age 18-65 meeting dsm-v criteria for moderate or severe aud in the past year; * interested in cutting down or quitting drinking; * able to provide voluntary informed consent; * have at least 4 heavy drinking days (≥ 5 drinks per day for men, and ≥4 for women) in the past 60 days; * currently receiving treatment for alcohol use disorder. exclusion criteria: * severe neurological conditions (tbi/stroke/history of a seizure/dementia and other significant cognitive illnesses); * other urgent medical problems, as determined by the study physician from the history and physical exam; * schizophrenia, schizoaffective disorder, bipolar i disorder * suicidal thoughts (intent or plan) in the last month; * current moderate or severe other sud (except nicotine or marijuana) or other drug (except nicotine or marijuana) use in the past month; * active legal problems with the potential to result in incarceration; * pregnancy or lactation, or child bearing age and sexually active but not on birth control (barrier methods allowed); * current daily use of anti-craving medications, antidepressants (at doses considered therapeutic for depression), benzodiazepines, antipsychotics (at doses considered therapeutic for psychosis or mood stabilization), mood stabilizers (at doses considered therapeutic for mood stabilization); * have previously undergone rtms (to assure the blind is effective); * personal or familial (in first degree relatives) history of epilepsy; * any contraindication for magnetic resonance imaging (mri) or tms including metal shards or certain implants (pacemakers etc.) in the body.

Keywords: rtms
effect of adde on tear interferometry

Conditions: Tear; Dry Eye Syndromes

Summary: importance: lipid layer thickness (llt) reflects the lipid components of tear film, but is affected by the mucocutaneous components. this study investigated the therapeutic effect of the treatments for aqueous-deficient dry eye (adde) on llt. objective: to investigate the effect of adde and its treatments on llt measurements by tear interferometry. design, setting, and participants: this prospective comparative interventional study included 152 eyes from 152 patients with adde. interventions: participants were classified into four groups: control group (group 1), 3% diquafosol group (group 2), punctal plug insertion group (group 3), and combined treatment group (group 4). main outcomes and measures: average llt (lltave) was measured using a lipiview® ii tear interferometer at baseline and one month after treatments.


Eligibility criteria:
inclusion criteria: 1. presence of one or more subjective symptoms of ded, including eye dryness, foreign body sensation, irritation, burning, blurred vision, and pain. 2. tear meniscus height (tmh) of \<200 µm for aqueous deficiency measured using keratograph 5m® (oculus optikgeräte gmbh, wetzlar, germany). 3. evidence of corneal and/or conjunctival damage on slit-lamp biomicroscopy with fluorescein staining. exclusion criteria: 1. acute and chronic ocular surface diseases that affect ded, including infection, allergy, and autoimmune disease, and that interfere with tear interferometric measurements, such as corneal opacity and pterygium, were excluded. 2. a history of the use of contact lens, known systemic diseases such as sjögren's syndrome, stevens-johnson syndrome, and ocular graft-versus-host disease. 3. any medical/surgical history related to tear production and tear function except that in the study protocol were excluded. 4. hypersecretory meibomian gland dysfunction (mgd) * when both eyes of a patient could be included, an eye with the lower tmh was selected.
neurobehavioral model of hiv in injection drug users

Conditions: Drug Abuse; HIV Infections

Summary: the purpose of this r01 study is to evaluate the association between neuropsychological executive dysfunction and hiv infection among young injection and non-injection drug users. a longitudinal study will be conducted in which the cohort of seronegative drug users completing a baseline neuropsychological battery are re-assessed on three subsequent occasions, roughly six months apart. the primary aim of the longitudinal study is to estimate the magnitude of the suspected causal relationship between executive dysfunction and hiv-risk behaviors while adjusting for time-invariant (e.g. sex, ethnicity) and time-varying (e.g. degree of drug abuse) covariates. we also seek to evaluate: (1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and hiv-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and hiv-risk-behaviors. if successful, this project will shed new light on significant and potentially malleable hiv-risk factors in injection and non-injection drug users. this will be important evidence because injection drug abuse continues to account for a large proportion of hiv seroconversions particularly among young women and minorities. as such, this ro1 research project serves as an important initial step in a line of innovative investigations about suspected causal associations between neuropsychological deficits and hiv-risk behaviors in drug users. ultimately, this line of investigation should lead to changes in public and clinical practices designed to prevent hiv infection.


Eligibility criteria:
inclusion criteria: * drug users aged 15 to 50 years old. exclusion criteria: * acute psychotic, suicidal, homicidal ideation.

Keywords: hiv epidemiology neurology neuropsychological hiv risk factors cognitive risk factors hiv